Joining Forces to Accelerate Our Oncology Portfolio
Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune-mediated diseases. AbbVie's acquisition of Pharmacyclics is a strategically compelling opportunity that enables us to build a strong leadership position in hematological oncology, where there is significant unmet need.
Partnering with MD Anderson to Advance Immunotherapy
AbbVie's recent collaboration with the immunotherapy platform at the University of Texas MD Anderson Cancer Center will empower us to find new ways to unleash the immune system's potential to fight cancer.
Pairing MD Anderson's cutting-edge preclinical, translational and clinical capabilities with AbbVie's innovative discovery and development programs accelerates our ability to deliver new therapies that can help transform the lives of people affected by cancer.
Facilitating Deeper Collaboration in the Oncology Community
We recognize the value of every voice and mind in the oncology community. We hope that sharing our knowledge and science with the larger professional oncology community will encourage curiosity and healthy dialogue, the outcome of which may lead to greater opportunities to help address areas of unmet needs on behalf of people affected by cancer.
AbbVie is dedicated to tackling the toughest challenges in oncology, through our own research and through strategic collaborations with external organizations, in order to advance our science.
These partnerships are developed to pursue two critical goals: discovering and developing new medicines and improving patient outcomes. Our partners share this patient-focused commitment to help address areas of unmet needs in oncology.
We are proud to work with a range of organizations—including the select list below—to make a remarkable impact on the lives of people affected by cancer around the world:
Visit AbbVie.com/Oncology to view our full list of collaboration partners.